No Data
No Data
CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note
Actinium Wins FDA Nod to Conduct Clinical Trial for Radiotherapy
CRISPR Therapeutics Stock Is Approaching Its 52-Week Low
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know
TD Cowen Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Maintains Target Price $30
Agilent to Acquire North American CDMO BIOVECTRA
No Data